Grail, Inc. (NASDAQ:GRAL) Short Interest Update

Grail, Inc. (NASDAQ:GRAL) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 3,530,000 shares, a growth of 6.6% from the October 15th total of 3,310,000 shares. Currently, 13.5% of the company’s shares are short sold. Based on an average daily volume of 750,800 shares, the days-to-cover ratio is currently 4.7 days.

Insider Buying and Selling

In other Grail news, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now directly owns 612,661 shares in the company, valued at approximately $8,589,507.22. The trade was a 16.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Chun R. Ding bought 7,629 shares of Grail stock in a transaction dated Tuesday, October 1st. The stock was acquired at an average price of $13.52 per share, with a total value of $103,144.08. Following the acquisition, the insider now directly owns 3,503,655 shares of the company’s stock, valued at approximately $47,369,415.60. This represents a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 58,829 shares of company stock valued at $757,298.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Guggenheim began coverage on shares of Grail in a research report on Thursday, October 17th. They issued a “neutral” rating for the company. Wolfe Research began coverage on shares of Grail in a research report on Friday. They issued a “peer perform” rating for the company.

Grail Trading Down 5.4 %

GRAL traded down $0.80 during trading on Monday, reaching $14.00. 1,377,515 shares of the stock traded hands, compared to its average volume of 1,096,653. The firm’s 50-day moving average price is $13.82. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $23.36.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.